Skip to main content
Top
Published in:

Open Access 17-06-2024 | Tricuspid Valve Replacement | Structural Heart Disease (S Vakamudi, Section Editor)

Transcatheter Therapy for the Tricuspid Valve: A Focused Review of Edge-to-Edge Repair and Orthotopic Valve Replacement

Authors: Mahesh V. Madhavan, Vratika Agarwal, Rebecca T. Hahn

Published in: Current Cardiology Reports | Issue 6/2024

Login to get access

Abstract

Purpose of Review

Patients with severe tricuspid regurgitation (TR) are at risk for significant morbidity and mortality. Transcatheter tricuspid valve interventions (TTVI) may offer patients less invasive treatment alternatives to surgery. This review evaluates the most common class of device currently used worldwide to treat TR, tricuspid transcatheter edge-to-edge repair (T-TEER) and orthotopic transcatheter tricuspid valve replacement (TTVR), both of which are now approved in the USA and Europe.

Recent Findings

The first pivotal randomized clinical trial, TRILUMINATE, demonstrated that T-TEER can safely reduce TR and is associated with improved health status outcomes. However, results of this trial have raised questions about whether this device can provide sufficient TR reduction to impact clinical outcomes. Orthotopic TTVR has recently gained attention with initial data suggesting near-complete TR elimination.

Summary

The current review examines the technical features and anatomic limitations of the most commonly used devices for T-TEER and orthotopic TTVR, discusses the current clinical data for these devices, and offers a theoretical construct for device selection.
Literature
1.
go back to reference • Hahn RT. Tricuspid regurgitation. N Engl J Med. 2023;388:1876–91. This comprehensive review summarizes the anatomy, pathophysiology, epidemiology, and available clinical data for tricuspid valve disease.PubMedCrossRef • Hahn RT. Tricuspid regurgitation. N Engl J Med. 2023;388:1876–91. This comprehensive review summarizes the anatomy, pathophysiology, epidemiology, and available clinical data for tricuspid valve disease.PubMedCrossRef
2.
go back to reference Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43:405–9.PubMedCrossRef Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43:405–9.PubMedCrossRef
3.
go back to reference Offen S, Playford D, Strange G, Stewart S, Celermajer DS. Adverse prognostic impact of even mild or moderate tricuspid regurgitation: insights from the National Echocardiography Database of Australia. J Am Soc Echocardiogr. 2022;35:810–7.PubMedCrossRef Offen S, Playford D, Strange G, Stewart S, Celermajer DS. Adverse prognostic impact of even mild or moderate tricuspid regurgitation: insights from the National Echocardiography Database of Australia. J Am Soc Echocardiogr. 2022;35:810–7.PubMedCrossRef
4.
go back to reference Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74:2998–3008.PubMedCrossRef Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74:2998–3008.PubMedCrossRef
5.
6.
go back to reference Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2021;77:450–500.PubMedCrossRef Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2021;77:450–500.PubMedCrossRef
7.
go back to reference Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632.PubMedCrossRef Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632.PubMedCrossRef
8.
go back to reference Chen Q, Bowdish ME, Malas J, Roach A, Gill G, Rowe G, et al. Isolated tricuspid operations: the society of thoracic surgeons adult cardiac surgery database analysis. Ann Thorac Surg. 2023;115:1162–70.PubMedPubMedCentralCrossRef Chen Q, Bowdish ME, Malas J, Roach A, Gill G, Rowe G, et al. Isolated tricuspid operations: the society of thoracic surgeons adult cardiac surgery database analysis. Ann Thorac Surg. 2023;115:1162–70.PubMedPubMedCentralCrossRef
9.
go back to reference Scotti A, Sturla M, Granada JF, Kodali SK, Coisne A, Mangieri A, et al. Outcomes of isolated tricuspid valve replacement: a systematic review and meta-analysis of 5,316 patients from 35 studies. EuroIntervention. 2022;18:840–51.PubMedPubMedCentralCrossRef Scotti A, Sturla M, Granada JF, Kodali SK, Coisne A, Mangieri A, et al. Outcomes of isolated tricuspid valve replacement: a systematic review and meta-analysis of 5,316 patients from 35 studies. EuroIntervention. 2022;18:840–51.PubMedPubMedCentralCrossRef
10.
go back to reference Hahn RT, Brener MI, Cox ZL, Pinney S, Lindenfeld J. Tricuspid regurgitation management for heart failure. JACC Heart Fail. 2023;11:1084–102.PubMedCrossRef Hahn RT, Brener MI, Cox ZL, Pinney S, Lindenfeld J. Tricuspid regurgitation management for heart failure. JACC Heart Fail. 2023;11:1084–102.PubMedCrossRef
11.
go back to reference Wang N, Fulcher J, Abeysuriya N, McGrady M, Wilcox I, Celermajer D, et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. Eur Heart J. 2019;40:476–84.PubMedCrossRef Wang N, Fulcher J, Abeysuriya N, McGrady M, Wilcox I, Celermajer D, et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. Eur Heart J. 2019;40:476–84.PubMedCrossRef
12.
go back to reference Hahn RT, Badano LP, Bartko PE, Muraru D, Maisano F, Zamorano JL, et al. Tricuspid regurgitation: recent advances in understanding pathophysiology, severity grading and outcome. Eur Heart J Cardiovas Imaging. 2022. Hahn RT, Badano LP, Bartko PE, Muraru D, Maisano F, Zamorano JL, et al. Tricuspid regurgitation: recent advances in understanding pathophysiology, severity grading and outcome. Eur Heart J Cardiovas Imaging. 2022.
13.
go back to reference Hahn RT, Lerakis S, Delgado V, Addetia K, Burkhoff D, Muraru D, et al. Multimodality imaging of right heart function: JACC scientific statement. J Am Coll Cardiol. 2023;81:1954–73.PubMedCrossRef Hahn RT, Lerakis S, Delgado V, Addetia K, Burkhoff D, Muraru D, et al. Multimodality imaging of right heart function: JACC scientific statement. J Am Coll Cardiol. 2023;81:1954–73.PubMedCrossRef
14.
go back to reference Agarwal V, Hahn R. Tricuspid regurgitation and right heart failure: the role of imaging in defining pathophysiology, presentation, and novel management strategies. Heart Fail Clin. 2023;19:505–23.PubMedCrossRef Agarwal V, Hahn R. Tricuspid regurgitation and right heart failure: the role of imaging in defining pathophysiology, presentation, and novel management strategies. Heart Fail Clin. 2023;19:505–23.PubMedCrossRef
15.
go back to reference Alfieri O, Denti P. Alfieri stitch and its impact on mitral clip. Eur J Cardiothorac Surg. 2011;39:807–8.PubMedCrossRef Alfieri O, Denti P. Alfieri stitch and its impact on mitral clip. Eur J Cardiothorac Surg. 2011;39:807–8.PubMedCrossRef
16.
go back to reference Hahn RT, Saric M, Faletra FF, Garg R, Gillam LD, Horton K, et al. Recommended standards for the performance of transesophageal echocardiographic screening for structural heart intervention: from the American Society of Echocardiography. J Am Soc Echocardiogr. 2022;35:1–76.PubMedCrossRef Hahn RT, Saric M, Faletra FF, Garg R, Gillam LD, Horton K, et al. Recommended standards for the performance of transesophageal echocardiographic screening for structural heart intervention: from the American Society of Echocardiography. J Am Soc Echocardiogr. 2022;35:1–76.PubMedCrossRef
17.
go back to reference Eleid MF, Alkhouli M, Thaden JJ, Zahr F, Chadderdon S, Guerrero M, et al. Utility of intracardiac echocardiography in the early experience of transcatheter edge to edge tricuspid valve repair. Circ Cardiovasc Interv. 2021;14:e011118.PubMedCrossRef Eleid MF, Alkhouli M, Thaden JJ, Zahr F, Chadderdon S, Guerrero M, et al. Utility of intracardiac echocardiography in the early experience of transcatheter edge to edge tricuspid valve repair. Circ Cardiovasc Interv. 2021;14:e011118.PubMedCrossRef
18.
go back to reference von Bardeleben RS, Lurz P, Sorajja P, Ruf T, Hausleiter J, Sitges M, et al. Two-year outcomes for tricuspid repair with a transcatheter edge-to-edge valve repair from the transatlantic TRILUMINATE trial. Circ Cardiovasc Interv. 2023;16:e012888. von Bardeleben RS, Lurz P, Sorajja P, Ruf T, Hausleiter J, Sitges M, et al. Two-year outcomes for tricuspid repair with a transcatheter edge-to-edge valve repair from the transatlantic TRILUMINATE trial. Circ Cardiovasc Interv. 2023;16:e012888.
19.
go back to reference •• Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388:1833–42. This study marks the first pivotal randomized clinical trial evaluating the use of triscuspid transcatheter edge-to-edge repair in patients with tricuspid regurgitation. •• Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388:1833–42. This study marks the first pivotal randomized clinical trial evaluating the use of triscuspid transcatheter edge-to-edge repair in patients with tricuspid regurgitation.
20.
go back to reference Maznyczka A, Pilgrim T. Antithrombotic treatment after transcatheter valve interventions: current status and future directions. Clin Ther. 2023. Maznyczka A, Pilgrim T. Antithrombotic treatment after transcatheter valve interventions: current status and future directions. Clin Ther. 2023.
21.
go back to reference Greenbaum AB, Babaliaros VC, Eng MH. Orthotopic transcatheter tricuspid valve replacement. Interv Cardiol Clin. 2022;11:87–94.PubMed Greenbaum AB, Babaliaros VC, Eng MH. Orthotopic transcatheter tricuspid valve replacement. Interv Cardiol Clin. 2022;11:87–94.PubMed
22.
go back to reference Webb J, Hensey M, Fam N, Rodés-Cabau J, Daniels D, Smith R, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv. 2020;13:2418–26.PubMedCrossRef Webb J, Hensey M, Fam N, Rodés-Cabau J, Daniels D, Smith R, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv. 2020;13:2418–26.PubMedCrossRef
23.
go back to reference Fam NP, von Bardeleben RS, Hensey M, Kodali SK, Smith RL, Hausleiter J, et al. Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. 2021;14:501–11.PubMedCrossRef Fam NP, von Bardeleben RS, Hensey M, Kodali SK, Smith RL, Hausleiter J, et al. Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. 2021;14:501–11.PubMedCrossRef
24.
go back to reference Webb JG, Chuang AM, Meier D, von Bardeleben RS, Kodali SK, Smith RL, et al. Transcatheter tricuspid valve replacement with the EVOQUE system: 1-year outcomes of a multicenter, first-in-human experience. JACC Cardiovasc Interv. 2022;15:481–91.PubMedCrossRef Webb JG, Chuang AM, Meier D, von Bardeleben RS, Kodali SK, Smith RL, et al. Transcatheter tricuspid valve replacement with the EVOQUE system: 1-year outcomes of a multicenter, first-in-human experience. JACC Cardiovasc Interv. 2022;15:481–91.PubMedCrossRef
25.
go back to reference Kodali S, Hahn RT, George I, Davidson CJ, Narang A, Zahr F, et al. Transfemoral tricuspid valve replacement in patients with tricuspid regurgitation: TRISCEND study 30-day results. JACC Cardiovasc Interv. 2022;15:471–80.PubMedCrossRef Kodali S, Hahn RT, George I, Davidson CJ, Narang A, Zahr F, et al. Transfemoral tricuspid valve replacement in patients with tricuspid regurgitation: TRISCEND study 30-day results. JACC Cardiovasc Interv. 2022;15:471–80.PubMedCrossRef
26.
go back to reference Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ, et al. Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study. Eur Heart J. 2023;44:4862–73.PubMedCrossRef Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ, et al. Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study. Eur Heart J. 2023;44:4862–73.PubMedCrossRef
27.
go back to reference Tomlinson S, Rivas CG, Agarwal V, Lebehn M, Hahn RT. Multimodality imaging for transcatheter tricuspid valve repair and replacement. Front Cardiovasc Med. 2023;10:1171968.PubMedPubMedCentralCrossRef Tomlinson S, Rivas CG, Agarwal V, Lebehn M, Hahn RT. Multimodality imaging for transcatheter tricuspid valve repair and replacement. Front Cardiovasc Med. 2023;10:1171968.PubMedPubMedCentralCrossRef
28.
go back to reference Hahn RT, Lawlor MK, Davidson CJ, Badhwar V, Sannino A, Spitzer E, et al. Tricuspid valve academic research consortium definitions for tricuspid regurgitation and trial endpoints. J Am Coll Cardiol. 2023;82:1711–35.PubMedCrossRef Hahn RT, Lawlor MK, Davidson CJ, Badhwar V, Sannino A, Spitzer E, et al. Tricuspid valve academic research consortium definitions for tricuspid regurgitation and trial endpoints. J Am Coll Cardiol. 2023;82:1711–35.PubMedCrossRef
29.
go back to reference Dannenberg V, Koschutnik M, Donà C, Nitsche C, Mascherbauer K, Heitzinger G, et al. Invasive hemodynamic assessment and procedural success of transcatheter tricuspid valve repair-important factors for right ventricular remodeling and outcome. Front Cardiovasc Med. 2022;9:891468.PubMedPubMedCentralCrossRef Dannenberg V, Koschutnik M, Donà C, Nitsche C, Mascherbauer K, Heitzinger G, et al. Invasive hemodynamic assessment and procedural success of transcatheter tricuspid valve repair-important factors for right ventricular remodeling and outcome. Front Cardiovasc Med. 2022;9:891468.PubMedPubMedCentralCrossRef
30.
go back to reference Lurz P, Besler C, Schmitz T, Bekeredjian R, Nickenig G, Mollmann H, et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol. 2023;82:281–91.PubMedCrossRef Lurz P, Besler C, Schmitz T, Bekeredjian R, Nickenig G, Mollmann H, et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol. 2023;82:281–91.PubMedCrossRef
31.
go back to reference Wild MG, Löw K, Rosch S, Gerçek M, Higuchi S, Massberg S, et al. Multicenter experience with the transcatheter leaflet repair system for symptomatic tricuspid regurgitation. JACC Cardiovasc Interv. 2022;15:1352–63.PubMedCrossRef Wild MG, Löw K, Rosch S, Gerçek M, Higuchi S, Massberg S, et al. Multicenter experience with the transcatheter leaflet repair system for symptomatic tricuspid regurgitation. JACC Cardiovasc Interv. 2022;15:1352–63.PubMedCrossRef
32.
go back to reference Hahn RT, Weckbach LT, Noack T, Hamid N, Kitamura M, Bae R, et al. Proposal for a standard echocardiographic tricuspid valve nomenclature. JACC Cardiovasc Imaging. 2021. Hahn RT, Weckbach LT, Noack T, Hamid N, Kitamura M, Bae R, et al. Proposal for a standard echocardiographic tricuspid valve nomenclature. JACC Cardiovasc Imaging. 2021.
33.
go back to reference Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V, et al. Transcatheter treatment for tricuspid valve disease. EuroIntervention. 2021;17:791–808.PubMedPubMedCentralCrossRef Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V, et al. Transcatheter treatment for tricuspid valve disease. EuroIntervention. 2021;17:791–808.PubMedPubMedCentralCrossRef
34.
go back to reference Besler C, Orban M, Rommel KP, Braun D, Patel M, Hagl C, et al. Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair. JACC Cardiovasc Interv. 2018;11:1119–28.PubMedCrossRef Besler C, Orban M, Rommel KP, Braun D, Patel M, Hagl C, et al. Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair. JACC Cardiovasc Interv. 2018;11:1119–28.PubMedCrossRef
35.
go back to reference Ruf TF, Hahn RT, Kreidel F, Beiras-Fernandez A, Hell M, Gerdes P, et al. Short-term clinical outcomes of transcatheter tricuspid valve repair with the third-generation MitraClip XTR system. JACC Cardiovasc Interv. 2021;14:1231–40.PubMedCrossRef Ruf TF, Hahn RT, Kreidel F, Beiras-Fernandez A, Hell M, Gerdes P, et al. Short-term clinical outcomes of transcatheter tricuspid valve repair with the third-generation MitraClip XTR system. JACC Cardiovasc Interv. 2021;14:1231–40.PubMedCrossRef
36.
go back to reference Tanaka T, Sugiura A, Kavsur R, Vogelhuber J, Öztürk C, Becher MU, et al. Leaflet-to-annulus index and residual tricuspid regurgitation following tricuspid transcatheter edge-to-edge repair. EuroIntervention. 2022. Tanaka T, Sugiura A, Kavsur R, Vogelhuber J, Öztürk C, Becher MU, et al. Leaflet-to-annulus index and residual tricuspid regurgitation following tricuspid transcatheter edge-to-edge repair. EuroIntervention. 2022.
37.
go back to reference Taramasso M, Gavazzoni M, Pozzoli A, Alessandrini H, Latib A, Attinger-Toller A, et al. Outcomes of TTVI in patients with pacemaker or defibrillator leads: data from the TriValve registry. JACC Cardiovasc Interv. 2020;13:554–64.PubMedCrossRef Taramasso M, Gavazzoni M, Pozzoli A, Alessandrini H, Latib A, Attinger-Toller A, et al. Outcomes of TTVI in patients with pacemaker or defibrillator leads: data from the TriValve registry. JACC Cardiovasc Interv. 2020;13:554–64.PubMedCrossRef
38.
go back to reference Lurz J, Rommel KP, Unterhuber M, Besler C, Noack T, Borger M, et al. Safety and efficacy of transcatheter edge-to-edge repair of the tricuspid valve in patients with cardiac implantable electronic device leads. JACC Cardiovasc Interv. 2019;12:2114–6.PubMedCrossRef Lurz J, Rommel KP, Unterhuber M, Besler C, Noack T, Borger M, et al. Safety and efficacy of transcatheter edge-to-edge repair of the tricuspid valve in patients with cardiac implantable electronic device leads. JACC Cardiovasc Interv. 2019;12:2114–6.PubMedCrossRef
39.
go back to reference Kitamura M, Kresoja KP, Besler C, Leontyev S, Kiefer P, Rommel KP, et al. Impact of tricuspid valve morphology on clinical outcomes after transcatheter edge-to-edge repair. JACC Cardiovasc Interv. 2021;14:1616–8.PubMedCrossRef Kitamura M, Kresoja KP, Besler C, Leontyev S, Kiefer P, Rommel KP, et al. Impact of tricuspid valve morphology on clinical outcomes after transcatheter edge-to-edge repair. JACC Cardiovasc Interv. 2021;14:1616–8.PubMedCrossRef
40.
go back to reference Sugiura A, Tanaka T, Kavsur R, Öztürk C, Vogelhuber J, Wilde N. Leaflet configuration and residual tricuspid regurgitation after transcatheter edge-to-edge tricuspid repair. JACC Cardiovasc Interv. 2021;14:2260–70.PubMedCrossRef Sugiura A, Tanaka T, Kavsur R, Öztürk C, Vogelhuber J, Wilde N. Leaflet configuration and residual tricuspid regurgitation after transcatheter edge-to-edge tricuspid repair. JACC Cardiovasc Interv. 2021;14:2260–70.PubMedCrossRef
41.
go back to reference Webb JG, Wood DA, Ye J, Gurvitch R, Masson JB, Rodés-Cabau J, et al. Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation. 2010;121:1848–57.PubMedCrossRef Webb JG, Wood DA, Ye J, Gurvitch R, Masson JB, Rodés-Cabau J, et al. Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation. 2010;121:1848–57.PubMedCrossRef
42.
go back to reference Godart F, Baruteau AE, Petit J, Riou JY, Sassolas F, Lusson JR, et al. Transcatheter tricuspid valve implantation: a multicentre French study. Arch Cardiovasc Dis. 2014;107:583–91.PubMedCrossRef Godart F, Baruteau AE, Petit J, Riou JY, Sassolas F, Lusson JR, et al. Transcatheter tricuspid valve implantation: a multicentre French study. Arch Cardiovasc Dis. 2014;107:583–91.PubMedCrossRef
43.
go back to reference McElhinney DB, Aboulhosn JA, Dvir D, Whisenant B, Zhang Y, Eicken A, et al. Mid-term valve-related outcomes after transcatheter tricuspid valve-in-valve or valve-in-ring replacement. J Am Coll Cardiol. 2019;73:148–57.PubMedCrossRef McElhinney DB, Aboulhosn JA, Dvir D, Whisenant B, Zhang Y, Eicken A, et al. Mid-term valve-related outcomes after transcatheter tricuspid valve-in-valve or valve-in-ring replacement. J Am Coll Cardiol. 2019;73:148–57.PubMedCrossRef
44.
go back to reference Navia JL, Kapadia S, Elgharably H, Harb SC, Krishnaswamy A, Unai S, et al. First-in-human implantations of the navigate bioprosthesis in a severely dilated tricuspid annulus and in a failed tricuspid annuloplasty ring. Circ Cardiovasc Interv. 2017;10. Navia JL, Kapadia S, Elgharably H, Harb SC, Krishnaswamy A, Unai S, et al. First-in-human implantations of the navigate bioprosthesis in a severely dilated tricuspid annulus and in a failed tricuspid annuloplasty ring. Circ Cardiovasc Interv. 2017;10.
45.
go back to reference Hahn RT, George I, Kodali SK, Nazif T, Khalique OK, Akkoc D, et al. Early single-site experience with transcatheter tricuspid valve replacement. JACC Cardiovasc Imaging. 2019;12:416–29.PubMedCrossRef Hahn RT, George I, Kodali SK, Nazif T, Khalique OK, Akkoc D, et al. Early single-site experience with transcatheter tricuspid valve replacement. JACC Cardiovasc Imaging. 2019;12:416–29.PubMedCrossRef
46.
go back to reference Lu FL, Ma Y, An Z, Cai CL, Li BL, Song ZG, et al. First-in-man experience of transcatheter tricuspid valve replacement with lux-valve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv. 2020;13:1614–6.PubMedCrossRef Lu FL, Ma Y, An Z, Cai CL, Li BL, Song ZG, et al. First-in-man experience of transcatheter tricuspid valve replacement with lux-valve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv. 2020;13:1614–6.PubMedCrossRef
47.
go back to reference Barreiro-Perez M, Estevez-Loureiro R, Baz JA, Piñón MA, Maisano F, Puga L, et al. Cardiovalve transfemoral tricuspid valve replacement assisted with CT-fluoroscopy fusion imaging. JACC Cardiovasc Interv. 2022;15:e197–9.PubMedCrossRef Barreiro-Perez M, Estevez-Loureiro R, Baz JA, Piñón MA, Maisano F, Puga L, et al. Cardiovalve transfemoral tricuspid valve replacement assisted with CT-fluoroscopy fusion imaging. JACC Cardiovasc Interv. 2022;15:e197–9.PubMedCrossRef
48.
go back to reference Zhang Y, Lu F, Li W, Chen S, Li M, Zhang X, et al. A first-in-human study of transjugular transcatheter tricuspid valve replacement with the LuX-Valve Plus system. EuroIntervention. 2023;18:e1088–9.PubMedPubMedCentralCrossRef Zhang Y, Lu F, Li W, Chen S, Li M, Zhang X, et al. A first-in-human study of transjugular transcatheter tricuspid valve replacement with the LuX-Valve Plus system. EuroIntervention. 2023;18:e1088–9.PubMedPubMedCentralCrossRef
49.
50.
go back to reference •• Kodali S, on behalf of the TRISCEND II investigators. TRISCEND II trial: a randomized trial of transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation. Presented at: TCT 2023. October 26, 2023. San Francisco, CA. This presentation includes initial data from the first pivotal randomized clinical trial evaluating orthotopic transcatheter tricuspid valve replacement. •• Kodali S, on behalf of the TRISCEND II investigators. TRISCEND II trial: a randomized trial of transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation. Presented at: TCT 2023. October 26, 2023. San Francisco, CA. This presentation includes initial data from the first pivotal randomized clinical trial evaluating orthotopic transcatheter tricuspid valve replacement.
51.
go back to reference Lurz P, Stephan von Bardeleben R, Weber M, Sitges M, Sorajja P, Hausleiter J, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol. 2021;77:229–39.PubMedCrossRef Lurz P, Stephan von Bardeleben R, Weber M, Sitges M, Sorajja P, Hausleiter J, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol. 2021;77:229–39.PubMedCrossRef
52.
go back to reference Nickenig G, Weber M, Lurz P, von Bardeleben RS, Sitges M, Sorajja P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019;394:2002–11.PubMedCrossRef Nickenig G, Weber M, Lurz P, von Bardeleben RS, Sitges M, Sorajja P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019;394:2002–11.PubMedCrossRef
53.
go back to reference Arnold SV, Goates S, Sorajja P, Adams DH, Stephan von Bardeleben R, Kapadia SR, et al. Health status after transcatheter tricuspid-valve repair in patients with severe tricuspid regurgitation: results from the TRILUMINATE pivotal trial. J Am Coll Cardiol. 2023. Arnold SV, Goates S, Sorajja P, Adams DH, Stephan von Bardeleben R, Kapadia SR, et al. Health status after transcatheter tricuspid-valve repair in patients with severe tricuspid regurgitation: results from the TRILUMINATE pivotal trial. J Am Coll Cardiol. 2023.
54.
go back to reference Fam NP, Braun D, von Bardeleben RS, Nabauer M, Ruf T, Connelly KA, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. 2019;12:2488–95.PubMedCrossRef Fam NP, Braun D, von Bardeleben RS, Nabauer M, Ruf T, Connelly KA, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. 2019;12:2488–95.PubMedCrossRef
55.
go back to reference Kodali S, Hahn RT, Eleid MF, Kipperman R, Smith R, Lim DS, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. 2021;77:345–56.PubMedCrossRef Kodali S, Hahn RT, Eleid MF, Kipperman R, Smith R, Lim DS, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. 2021;77:345–56.PubMedCrossRef
56.
go back to reference Kodali SK, Hahn RT, Davidson CJ, Narang A, Greenbaum A, Gleason P, et al. 1-year outcomes of transcatheter tricuspid valve repair. J Am Coll Cardiol. 2023;81:1766–76.PubMedCrossRef Kodali SK, Hahn RT, Davidson CJ, Narang A, Greenbaum A, Gleason P, et al. 1-year outcomes of transcatheter tricuspid valve repair. J Am Coll Cardiol. 2023;81:1766–76.PubMedCrossRef
57.
go back to reference Aurich M, Volz MJ, Mereles D, Geis NA, Frey N, Konstandin MH, et al. Initial experience with the PASCAL ace implant system for treatment of severe tricuspid regurgitation. Circ Cardiovasc Interv. 2021;14:e010770.PubMedCrossRef Aurich M, Volz MJ, Mereles D, Geis NA, Frey N, Konstandin MH, et al. Initial experience with the PASCAL ace implant system for treatment of severe tricuspid regurgitation. Circ Cardiovasc Interv. 2021;14:e010770.PubMedCrossRef
58.
go back to reference Wang DD. PASCAL (CLASP IITR update). Phoenix, Arizona: TVT 2023; 2023. Wang DD. PASCAL (CLASP IITR update). Phoenix, Arizona: TVT 2023; 2023.
59.
go back to reference Prihadi EA, Delgado V, Leon MB, Enriquez-Sarano M, Topilsky Y, Bax JJ. Morphologic types of tricuspid regurgitation: characteristics and prognostic implications. JACC Cardiovasc Imag. 2019;12:491–9.CrossRef Prihadi EA, Delgado V, Leon MB, Enriquez-Sarano M, Topilsky Y, Bax JJ. Morphologic types of tricuspid regurgitation: characteristics and prognostic implications. JACC Cardiovasc Imag. 2019;12:491–9.CrossRef
60.
go back to reference Zhang XX, Wei M, Xiang R, Lu YM, Zhang L, Li YD, et al. Incidence, risk factors, and prognosis of tricuspid regurgitation after cardiac implantable electronic device implantation: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2022;36:1741–55.PubMedCrossRef Zhang XX, Wei M, Xiang R, Lu YM, Zhang L, Li YD, et al. Incidence, risk factors, and prognosis of tricuspid regurgitation after cardiac implantable electronic device implantation: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2022;36:1741–55.PubMedCrossRef
61.
go back to reference Stankovic I, Voigt J-U, Burri H, Muraru D, Sade LE, Haugaa KH, et al. Imaging in patients with cardiovascular implantable electronic devices: part 2—imaging after device implantation. A clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI) and the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J Cardiovasc Imag. 2023;25:e33–54.CrossRef Stankovic I, Voigt J-U, Burri H, Muraru D, Sade LE, Haugaa KH, et al. Imaging in patients with cardiovascular implantable electronic devices: part 2—imaging after device implantation. A clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI) and the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J Cardiovasc Imag. 2023;25:e33–54.CrossRef
62.
go back to reference Sorajja P, Sato H, Abdelhadi R, Zakaib J, Enriquez-Sarano M, Bapat V, et al. The impact and outcomes of RV lead extraction in CIED-related tricuspid regurgitation. JACC Cardiovasc Interv. 2023. Sorajja P, Sato H, Abdelhadi R, Zakaib J, Enriquez-Sarano M, Bapat V, et al. The impact and outcomes of RV lead extraction in CIED-related tricuspid regurgitation. JACC Cardiovasc Interv. 2023.
63.
go back to reference Blusztein DI, Hahn RT. New therapeutic approach for tricuspid regurgitation: transcatheter tricuspid valve replacement or repair. Front Cardiovasc Med. 2023;10. Blusztein DI, Hahn RT. New therapeutic approach for tricuspid regurgitation: transcatheter tricuspid valve replacement or repair. Front Cardiovasc Med. 2023;10.
64.
go back to reference Sala A, Hahn RT, Kodali SK, Mack MJ, Maisano F. Tricuspid valve regurgitation: current understanding and novel treatment options. J Soc Cardiovas Angiogr Interv. 2023;101041. Sala A, Hahn RT, Kodali SK, Mack MJ, Maisano F. Tricuspid valve regurgitation: current understanding and novel treatment options. J Soc Cardiovas Angiogr Interv. 2023;101041.
65.
go back to reference Stolz L, Weckbach LT, Hahn RT, Chatfield AG, Fam NP, von Bardeleben RS, et al. 2-year outcomes following transcatheter tricuspid valve replacement using the EVOQUE system. J Am Coll Cardiol. 2023;81:2374–6.PubMedCrossRef Stolz L, Weckbach LT, Hahn RT, Chatfield AG, Fam NP, von Bardeleben RS, et al. 2-year outcomes following transcatheter tricuspid valve replacement using the EVOQUE system. J Am Coll Cardiol. 2023;81:2374–6.PubMedCrossRef
66.
go back to reference Danenberg HD, Topilsky Y, Planer D, Maor E, Guetta V, Sievert H, et al. Tricuspid valve repair by chordal grasping: mistral first-in-human trial results at 6 months. JACC Cardiovasc Interv. 2023;16:244–6.PubMedCrossRef Danenberg HD, Topilsky Y, Planer D, Maor E, Guetta V, Sievert H, et al. Tricuspid valve repair by chordal grasping: mistral first-in-human trial results at 6 months. JACC Cardiovasc Interv. 2023;16:244–6.PubMedCrossRef
67.
go back to reference Piayda K, Bertog S, Steffan J, Ilioska-Damkohler P, Beeri R, Sievert K, et al. One-year outcomes of transcatheter tricuspid valve repair with the Mistral device. EuroIntervention. 2023;19:e363–5.PubMedCrossRef Piayda K, Bertog S, Steffan J, Ilioska-Damkohler P, Beeri R, Sievert K, et al. One-year outcomes of transcatheter tricuspid valve repair with the Mistral device. EuroIntervention. 2023;19:e363–5.PubMedCrossRef
68.
go back to reference Perlman G, Praz F, Puri R, Ofek H, Ye J, Philippon F, et al. Transcatheter tricuspid valve repair with a new transcatheter coaptation system for the treatment of severe tricuspid regurgitation: 1-year clinical and echocardiographic results. JACC Cardiovasc Interv. 2017;10:1994–2003.PubMedCrossRef Perlman G, Praz F, Puri R, Ofek H, Ye J, Philippon F, et al. Transcatheter tricuspid valve repair with a new transcatheter coaptation system for the treatment of severe tricuspid regurgitation: 1-year clinical and echocardiographic results. JACC Cardiovasc Interv. 2017;10:1994–2003.PubMedCrossRef
69.
go back to reference Asmarats L, Perlman G, Praz F, Hensey M, Chrissoheris MP, Philippon F, et al. Long-term outcomes of the FORMA transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation: insights from the first-in-human experience. JACC Cardiovasc Interv. 2019;12:1438–47.PubMedCrossRef Asmarats L, Perlman G, Praz F, Hensey M, Chrissoheris MP, Philippon F, et al. Long-term outcomes of the FORMA transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation: insights from the first-in-human experience. JACC Cardiovasc Interv. 2019;12:1438–47.PubMedCrossRef
70.
go back to reference Meduri C, Hahn R, Davidson C, Lim S, Nazif T, Ricciardi M, et al. TCT-74 SCOUT study: Trialign results at 30 days from combined US and EU cohort for the treatment of functional TR. J Am Coll Cardiol. 2018;72:B32–3.CrossRef Meduri C, Hahn R, Davidson C, Lim S, Nazif T, Ricciardi M, et al. TCT-74 SCOUT study: Trialign results at 30 days from combined US and EU cohort for the treatment of functional TR. J Am Coll Cardiol. 2018;72:B32–3.CrossRef
71.
go back to reference Hahn RT, Meduri CU, Davidson CJ, Lim S, Nazif TM, Ricciardi MJ, et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. J Am Coll Cardiol. 2017;69:1795–806.PubMedCrossRef Hahn RT, Meduri CU, Davidson CJ, Lim S, Nazif TM, Ricciardi MJ, et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. J Am Coll Cardiol. 2017;69:1795–806.PubMedCrossRef
72.
go back to reference Zhang X, Jin Q, Pan W, Li W, Guo Y, Ma G, et al. First-in-human study of the K-Clip transcatheter annular repair system for severe functional tricuspid regurgitation. Int J Cardiol. 2023;390:131174.PubMedCrossRef Zhang X, Jin Q, Pan W, Li W, Guo Y, Ma G, et al. First-in-human study of the K-Clip transcatheter annular repair system for severe functional tricuspid regurgitation. Int J Cardiol. 2023;390:131174.PubMedCrossRef
73.
go back to reference Nickenig G, Weber M, Schüler R, Hausleiter J, Nabauer M, von Bardeleben RS, et al. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention. 2021;16:e1264–71.PubMedPubMedCentralCrossRef Nickenig G, Weber M, Schüler R, Hausleiter J, Nabauer M, von Bardeleben RS, et al. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention. 2021;16:e1264–71.PubMedPubMedCentralCrossRef
74.
go back to reference Gray WA, Abramson SV, Lim S, Fowler D, Smith RL, Grayburn PA, et al. Cardioband TREFSI. 1-year outcomes of Cardioband tricuspid valve reconstruction system early feasibility study. JACC Cardiovasc Interv. 2021;15:1921–32.CrossRef Gray WA, Abramson SV, Lim S, Fowler D, Smith RL, Grayburn PA, et al. Cardioband TREFSI. 1-year outcomes of Cardioband tricuspid valve reconstruction system early feasibility study. JACC Cardiovasc Interv. 2021;15:1921–32.CrossRef
75.
go back to reference Dreger H, Mattig I, Hewing B, Knebel F, Lauten A, Lembcke A, et al. Treatment of severe TRIcuspid regurgitation in patients with advanced heart failure with CAval vein implantation of the Edwards Sapien XT VALve (TRICAVAL): a randomised controlled trial. EuroIntervention. 2020;15:1506–13.PubMedCrossRef Dreger H, Mattig I, Hewing B, Knebel F, Lauten A, Lembcke A, et al. Treatment of severe TRIcuspid regurgitation in patients with advanced heart failure with CAval vein implantation of the Edwards Sapien XT VALve (TRICAVAL): a randomised controlled trial. EuroIntervention. 2020;15:1506–13.PubMedCrossRef
76.
go back to reference Estevez-Loureiro R, Sanchez-Recalde A, Amat-Santos IJ, Cruz-Gonzalez I, Baz JA, Pascual I, et al. 6-month outcomes of the TricValve system in patients with tricuspid regurgitation: the TRICUS EURO study. JACC Cardiovasc Interv. 2022;15:1366–77.PubMedCrossRef Estevez-Loureiro R, Sanchez-Recalde A, Amat-Santos IJ, Cruz-Gonzalez I, Baz JA, Pascual I, et al. 6-month outcomes of the TricValve system in patients with tricuspid regurgitation: the TRICUS EURO study. JACC Cardiovasc Interv. 2022;15:1366–77.PubMedCrossRef
77.
go back to reference Wild MG, Lubos E, Cruz-Gonzalez I, Amat-Santos I, Ancona M, Andreas M, et al. Early clinical experience with the TRICENTO bicaval valved stent for treatment of symptomatic severe tricuspid regurgitation: a multicenter registry. Circ Cardiovasc Interv. 2022;15:e011302.PubMedCrossRef Wild MG, Lubos E, Cruz-Gonzalez I, Amat-Santos I, Ancona M, Andreas M, et al. Early clinical experience with the TRICENTO bicaval valved stent for treatment of symptomatic severe tricuspid regurgitation: a multicenter registry. Circ Cardiovasc Interv. 2022;15:e011302.PubMedCrossRef
Metadata
Title
Transcatheter Therapy for the Tricuspid Valve: A Focused Review of Edge-to-Edge Repair and Orthotopic Valve Replacement
Authors
Mahesh V. Madhavan
Vratika Agarwal
Rebecca T. Hahn
Publication date
17-06-2024
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 6/2024
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-024-02051-4

Other articles of this Issue 6/2024

Current Cardiology Reports 6/2024 Go to the issue

Congenital Heart Disease (RA Krasuski and G Fleming, Section Editors)

Right Ventricle-Pulmonary Artery Coupling in Patients Undergoing Cardiac Interventions

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Applying AI to the humble ECG

Ischemic Heart Disease (D Mukherjee, Section Editor)

Polyvascular disease: a serious situation

Structural Heart Disease (S Vakamudi, Section Editor)

New options for managing pulmonary embolisms

Peripheral Vascular Disease (S Kinlay, Section Editor)

Improving outcomes in peripheral artery disease

Interventional Cardiology (SR Bailey and T Helmy, Section Editors)

Occupational Risks of Radiation Exposure to Cardiologists

Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine